Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the LATITUDE trial, a phase III trial on androgen deprivation therapy (ADT) with abiraterone in newly diagnosed, high-risk, metastatic prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Advertisement